Molecular Mechanisms of Cyclosporin A Inhibition of the Cytokine-induced Matrix Metalloproteinase-9 in Glomerular Mesangial Cells
Overview
Authors
Affiliations
The effects of the immunosuppressants cyclosporin A (CsA) and tacrolimus (FK506) on the IL-1beta-induced matrix metalloproteinase-9 (MMP-9) were investigated. Impairment of the protease-antiprotease balance contributes to renal fibrosis, which is observed collectively under long-term treatment with either immunosuppressant. It is demonstrated that CsA, in contrast to FK506, reduced the IL-1beta-induced MMP-9 content in conditioned media of mesangial cells, which coincides with a reduction in the cytokine-induced MMP-9 mRNA level. Similar to FK506, the VIVIT peptide, a specific inhibitor of the nuclear factor of activated T cells, did not affect the cytokine-induced MMP-9 level. Moreover, CsA caused a dose-dependent inhibition on the IL-1beta-induced luciferase activity of a 1.3-kb MMP-9 promoter fragment. Concomitant, electrophoretic mobility shift assay revealed that CsA selectively inhibits the cytokine-induced DNA binding of activator protein-1 and NF-kappaB. The effects on NF-kappaB binding were accompanied by a marked reduction in the nuclear content of the p65 subunit of NF-kappaB. Accordingly, CsA specifically impaired the IL-1beta-triggered degradation of inhibitory NF-kappaB. The suppressive effects by CsA on MMP-9 expression were accompanied by a reduction in the cytokine-induced phosphorylation of p42/p44 and c-Jun N-terminal Kinase (JNK). It is interesting that only the JNK inhibitor SP600125 impaired the cytokine-triggered MMP-9 level, suggesting that CsA, via inhibition of the JNK pathway, negatively interferes with the NF-kappaB-dependent transcriptional control of MMP-9. Interference with MMP-9 transcription may account for the accumulation of extracellular matrix underlying the high fibrotic potential of CsA during anti-inflammatory therapies with calcineurin inhibitors.
Lysyl oxidase inhibitors attenuate cyclosporin A-induced nephropathy in mouse.
Nguyen L, Saad S, Shi Y, Wang R, Chou A, Gill A Sci Rep. 2021; 11(1):12437.
PMID: 34127702 PMC: 8203624. DOI: 10.1038/s41598-021-91772-5.
Rashki A, Mumtaz F, Jazayeri F, Shadboorestan A, Esmaeili J, Ejtemaei Mehr S EXCLI J. 2019; 17:1137-1151.
PMID: 30713473 PMC: 6341459. DOI: 10.17179/excli2018-1693.
Emerging treatment options for the management of pemphigus vulgaris.
Kridin K Ther Clin Risk Manag. 2018; 14:757-778.
PMID: 29740210 PMC: 5931200. DOI: 10.2147/TCRM.S142471.
Cyclosporine A Induces MicroRNAs Controlling Innate Immunity during Renal Bacterial Infection.
Sadio M, Tourneur E, Bens M, Goujon J, Vandewalle A, Chassin C J Innate Immun. 2017; 10(1):14-29.
PMID: 29069656 PMC: 6757153. DOI: 10.1159/000480248.
Advances in Developing Therapies to Combat Zika Virus: Current Knowledge and Future Perspectives.
Munjal A, Khandia R, Dhama K, Sachan S, Karthik K, Tiwari R Front Microbiol. 2017; 8:1469.
PMID: 28824594 PMC: 5541032. DOI: 10.3389/fmicb.2017.01469.